Standards of care, therapeutic targets and future perspectives
Presidents: Giuseppe Curigliano, Paolo Marchetti, Andrea Botticelli
13 - 14 April 2026 Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome
Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics.
Detailed genomic screening is likely to play a central role in this.
Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention.
Personalized medicine promoters usually highlight its potential to combine a more effective health-care with cost containment, according to the following rules:
- Early intervention
- Selection of optimal therapy
- Reduction of trial-and-error prescribing and reduction of adverse drug reactions
- Exclusion of unnecessary drugs
- Therapeutic drug monitoring and disease progression/remission monitoring
- Increased patient compliance with therapy
But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country.
Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.
The aim of the meeting, where we are expecting approximately 150/200 participants from Italy and Europe, is to discuss with leading key opinion leaders about the future prospects of precision medicine and precision oncology and their application in real-world practice.
Le iscrizioni sono aperte. Per iscriversi contattare: info@didacktica.it
